408 related articles for article (PubMed ID: 12490790)
1. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression.
Mehra MR; Uber PA; Scott RL; Park MH
Transplantation; 2002 Dec; 74(11):1568-73. PubMed ID: 12490790
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits.
Mehra MR; Uber PA; Park MH; Ventura HO; Scott RL
Transplant Proc; 2004 Dec; 36(10):3152-5. PubMed ID: 15686716
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
6. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
7. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
[TBL] [Abstract][Full Text] [Related]
8. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients.
Roth D; Colona J; Burke GW; Ciancio G; Esquenazi V; Miller J
Transplantation; 1998 Jan; 65(2):248-52. PubMed ID: 9458023
[TBL] [Abstract][Full Text] [Related]
9. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.
Weber M; Deng S; Arenas J; Aradhye S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
Transplant Proc; 1997 Dec; 29(8):3669-70. PubMed ID: 9414883
[No Abstract] [Full Text] [Related]
10. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
12. Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group.
Neylan JF
Transplantation; 1998 Feb; 65(4):515-23. PubMed ID: 9500626
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid reduction with tacrolimus (CORRETA) TRIAL: a prospective Brazilian multicenter, randomized trial of early corticosteroid reduction versus regular corticosteroid dosage maintenance on a tacrolimus (Prograf) and mycophenolate mofetil (Cellcept) immunosuppression regimen in kidney transplant recipients: interim analysis.
Garcia VD; Carvalho DB; Goncalves RT; Cavalcanti RL; Campos HH; Abbud-Filho M; Lobao-Neto AA
Transplant Proc; 2008 Apr; 40(3):689-92. PubMed ID: 18454988
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
Meiser BM; Groetzner J; Kaczmarek I; Landwehr P; Müller M; Jung S; Uberfuhr P; Fraunberger P; Stempfle HU; Weis M; Reichart B
Transplantation; 2004 Aug; 78(4):591-8. PubMed ID: 15446320
[TBL] [Abstract][Full Text] [Related]
16. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
17. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection.
Yamani MH; Starling RC; Goormastic M; Van Lente F; Smedira N; McCarthy P; Young JB
Transplantation; 2000 Jun; 69(11):2326-30. PubMed ID: 10868634
[TBL] [Abstract][Full Text] [Related]
18. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
[No Abstract] [Full Text] [Related]
19. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases.
Kaufman DB; Leventhal JR; Stuart J; Abecassis MM; Fryer JP; Stuart FP
Transplantation; 1999 Feb; 67(4):586-93. PubMed ID: 10071032
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
Penson MG; Fricker FJ; Thompson JR; Harker K; Williams BJ; Kahler DA; Schowengerdt KO
J Heart Lung Transplant; 2001 Jun; 20(6):611-8. PubMed ID: 11404165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
